China National Pharmaceutical Group Co., Ltd. (Sinopharm) and MSD announced on Sept 28 that they had reached an agreement on import and distribution in China of a kind of anti-COVID-19 oral drug.
The two sides will also assess technology transfer of the drug to make its production, supply and commercialization convenient in the country.
The oral drug is a kind of small molecule COVID-19 treatment drug that has been approved for marketing and emergency use in more than 40 countries and regions.
By the end of August 2022, more than 1.8 million patients had been cured with the drug.
Once Sinopharm obtains the technology transferred by MSD it will promote domestic production and supply in China to support the fight against the pandemic.
(Executive editor: Wang Ruoting)
